

3B Pharmaceuticals and TetraKit Technologies Announce Strategic Collaboration for Joint Radioligand Therapy (RLT) Development.

Both companies will combine their advanced drug discovery and radiolabeling platforms to develop innovative targeted alpha therapies (TATs).

Berlin (DE) / Copenhagen (DK), April 10th 2025 — 3B Pharmaceuticals GmbH (3BP), a leader in the development of targeted radiopharmaceuticals, and TetraKit Technologies (TT), developing cutting-edge click chemistry radiolabeling technologies, today announced a strategic collaboration in the targeted radiotherapy field. This partnership will leverage the unique strengths of both companies towards development of a drug candidate, which can be labeled with astatine-211, a highly promising alpha particle-emitting radionuclide to treat cancer patients.

This collaboration has the potential to advance an emerging class of peptide radiopharmaceuticals labeled with astatine-211. "We are very excited to work with 3BP," said Andreas Jensen, CEO of TetraKit Technologies. "By combining our radiolabeling platform with the impressive drug discovery know-how and expertise of a highly reputable and established company such as 3BP, we are confident that we can advance the development of a ground-breaking novel drug that harnesses the promising properties of astatine-211 and sets the stage for further advances in the field."

About 3B Pharmaceuticals

3B Pharmaceuticals is committed to the research and development of radiopharmaceutical precision therapies designed to effectively target and destroy cancer cells while minimizing damage to healthy tissue. Using its dedicated technology platform 3BP developed a broad pipeline of novel compounds addressing innovative as well as established drug targets to deliver diagnostic and therapeutic radioisotopes to tumors. The company's mission is to advance the standard of care in precision oncology through innovative nuclear medicine solutions that address unmet medical needs.

About TetraKit Technologies

TetraKit Technologies (TT) develops an advanced click chemistry-based radiolabeling technology, the TetraKit Platform. This technology enables efficient and practical labeling of any biomolecule with radiohalogens or other radionuclides for theranostics, focusing on astatine-211, iodine-131, iodine-123 and fluorine-18. In addition, TT is advancing an in-house drug development program, combining its proprietary platform technology with in-licensed or public-domain and off-patent targeting vectors.

Media Contact:

Jan Michel
Director Finance & Corporate Development
3B Pharmaceuticals GmbH
Email: info@3b-pharma.com

Andreas Jensen
CEO
TetraKit Technologies ApS
Email: contact@tetrakit.com

About 3BP
www.3b-pharma.com

About TetraKit Technologies
www.tetrakit.com